New Advancements in Non-Prescription Daily Herpes Treatments

Viruxo Introduces an industry first patented ingredient into its effective daily herpes tablet.

Online PR News – 03-December-2009 – – Viruxo Introduces an industry first patented ingredient into its effective daily herpes tablet.

Viruxo, maker of an Advanced All-Natural Herpes Tablet, soon will release its new formula utilizing a patented ingredient in its new Lysoprine blend. Worldwide during the first quarter 2010 Viruxo will be releasing its “cutting edge” blend containing the first patented ingredient in its industry. This ingredient will drastically increase the absorption of Viruxo's already effective product.

Viruxo is the only All-Natural Daily Suppressant Therapy on the market. It is an immune system support supplement that provides the body the ability to prevent Herpes Outbreaks from occurring. It has been proven effective and they back up that claim with a free 30 day trial and a money-back guarantee. Because of its blend of 14 All-Natural synergistic ingredients, Viruxo has no known side-effects.

Utilizing the patented ingredient Bioperine in cooperation with Sabinsa corporation, Viruxo now has a significantly higher bio-availability of it's 14 premium quality synergistic ingredients. With this advancement, Viruxo has reduced its pill size by 25 percent creating an easier to swallow tablet that is more powerful than before.

The cost of Viruxo will remain the same at just under a dollar a day. The expense of the new advancement offsets the reduced ingredient weight. Viruxo's mission was stated to provide an effective daily suppressant formula at a fraction of the cost of similar products. This new advancement fits well within their mission.

Viruxo further states that although sites claim to have a cure for herpes, currently none exists and those statement are unethical and misleading. Fast developing advancements in the field show a promising herpes cure in the future but for now daily suppressants are the most effective alternative.

For more information visit: